At medical schools, pharma companies, and even at the FDA, biostatisticians and clinical researchers recognize that retrospective data when treated with appropriate bias-controlling statistical methods, can in fact be reliable, particularly as it points to direction of influence and the general magnitude of effect.

FORBES: Why The New Dendreon Analysis Does Matter -- And Why It Doesn't